Literature DB >> 6958352

Leukemic cell lysis pneumonopathy. A complication of treated myeloblastic leukemia.

A F Tryka, J J Godleski, C H Fanta.   

Abstract

The course of acute noninfectious pulmonary infiltrates in five patients with myeloblastic leukemia was evaluated. All had circulating blast cells (range, 245-192,000/mm3) and recently had received chemotherapeutic drugs for their leukemia. Within four days of the nadir of their leukocyte counts, a patchy, often multilobar pneumonitis developed. Cultures for bacteria, fungi, and viruses were all negative, and no clinical response was observed to broad-spectrum antibiotics. On lung biopsy, pathologic changes were characterized by diffuse alveolar damage with degenerating blast cells in the interstitium and in organizing alveolar exudates. No potential pathogenic organisms were seen on light or electron microscopy of the biopsy samples. In each case the pulmonary infiltrate resolved without specific therapy. We postulate that lysis of leukemic cells, with subsequent release of their enzyme contents, led to the diffuse alveolar damage observed pathologically. Leukemic cell lysis pneumonopathy may be one of the potential causes of pulmonary infiltrates in leukemic patients and can be distinguished pathologically by its distinctive pattern.

Entities:  

Mesh:

Year:  1982        PMID: 6958352     DOI: 10.1002/1097-0142(19821215)50:12<2763::aid-cncr2820501212>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised host.

Authors:  C Mayaud; J Cadranel
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

2.  Lysis pneumonopathy associated with the use of fludarabine phosphate.

Authors:  J J Crowley; L Knight; N Charan
Journal:  West J Med       Date:  1994-12

3.  Extracorporeal membrane oxygenation as a rescue therapy for acute respiratory failure during chemotherapy in a patient with acute myeloid leukemia.

Authors:  Sang Won Lee; Youn Seup Kim; Goohyeon Hong
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

4.  Safety, tolerability, and biomarkers of the treatment of mice with aerosolized Toll-like receptor ligands.

Authors:  Victoria Y Alfaro; David L Goldblatt; Gabriella R Valverde; Mark F Munsell; Lee J Quinton; Adam K Walker; Robert Dantzer; Atul Varadhachary; Brenton L Scott; Scott E Evans; Michael J Tuvim; Burton F Dickey
Journal:  Front Pharmacol       Date:  2014-02-06       Impact factor: 5.810

Review 5.  How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation.

Authors:  Georg Maschmeyer; J Peter Donnelly
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.